Is PTN (PTN) Halal?

AMEX Healthcare United States $35M
✓ HALAL
Confidence: 95/100
PTN (PTN) is Halal under 3 of 5 Shariah screening standards, including AAOIFI Standard 21. With a debt ratio of just 0.4% against the AAOIFI threshold of 30%, PTN comfortably passes the key financial ratio tests. The company operates in the Healthcare sector (Biotechnology), which is not a prohibited industry under Islamic finance principles.

Shariah Screening — 5 Standards

Based on financial data from June 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 0.4%
/ 30%
6.0%
/ 30%
0.1%
/ 30%
N/A ✓ HALAL
DJIM 0.4%
/ 33%
6.0%
/ 33%
0.1%
/ 33%
N/A ✓ HALAL
MSCI 5.0%
/ 33%
78.5%
/ 33%
0.9%
/ 33%
N/A ✗ NOT HALAL
S&P 0.4%
/ 33%
6.0%
/ 33%
0.1%
/ 33%
N/A ✓ HALAL
FTSE 5.0%
/ 33%
78.5%
/ 33%
0.9%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-8.26
P/B Ratio
3.1
EV/EBITDA
-1.7
EV: $21M
Revenue
$0
Beta
-0.1
Low volatility
Current Ratio
2.8

Profitability

Gross Margin -40.2%
Operating Margin -6315.8%
Net Margin -107.4%
Return on Equity (ROE) -378.7%
Return on Assets (ROA) -70.3%

Cash Flow & Balance Sheet

Operating Cash Flow-$21M
Free Cash Flow-$21M
Total Debt$163,781
Debt-to-Equity3.0
Current Ratio2.8
Total Assets$3M

Price & Trading

Last Close$20.65
50-Day MA$19.41
200-Day MA$13.12
Avg Volume34K
Beta-0.1
52-Week Range
$2.00
$33.00

About PTN (PTN)

CEO
Dr. Carl Spana Ph.D.
Employees
29
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
AMEX
Market Cap
$35M
Currency
USD

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is PTN (PTN) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), PTN is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is PTN's debt ratio?

PTN's debt ratio is 0.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.0%.

What are PTN's key financial metrics?

PTN has a market capitalization of $35M. The company maintains a gross margin of -40.2% and a net margin of -107.4%. Return on equity stands at -378.7%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.